Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To Other Drugs; Findings Suggest TUS Will Demonstrate Broad Antileukemic Activity Across AML Patients
Aptose宣佈在AACR期刊上發佈臨床前數據，證明Tuspetinib與Venetoclax聯合使用時對急性髓細胞白血病細胞具有獨特的作用機制和合成殺傷力；Tuspetinib可延長對其他藥物具有耐藥性的多種急性髓細胞白血病模型的存活性；研究結果表明，TUS將在急性髓細胞白血病患者中表現出廣泛的抗白血病活性
- Peer-reviewed publication details unique TUS mechanism of action
- TUS+VEN combination synthetic lethality overcomes resistance to VEN
- Tuspetinib prolongs survival in multiple AML models resistant to other drugs
- Findings suggest TUS will demonstrate broad antileukemic activity across AML patients
-
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling
- 經過同行評審的出版物詳細介紹了 TUS 的獨特行動機制
- TUS+VEN 組合的合成殺傷力克服了對 VEN 的阻力
- Tuspetinib可延長對其他藥物具有耐藥性的多種急性髓細胞白血病模型的存活時間
- 研究結果表明，TUS將在急性髓細胞白血病患者中表現出廣泛的抗白血病活性
- TUS+VEN+AZA 針對新診斷的急性髓細胞白血病患者的三聯一線治療現已報名
SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR), available online now (link).
聖地亞哥和多倫多，2024年12月12日（GLOBE NEWSWIRE）——開發高度差異化靶向藥物治療血液系統惡性腫瘤的臨床階段精準腫瘤公司Aptose Biosciences Inc.（「Aptose」 或 「公司」）（納斯達克股票代碼：APTO，多倫多證券交易所股票代碼：APS）今天宣佈在癌症研究中公佈了Aptose的主要血液學化合物塔斯佩替尼（TUS）的臨床前數據《通訊》是美國癌症研究協會（AACR）的期刊，現已上線（鏈接）。
The publication, entitled "Preclinical development of tuspetinib for the treatment of acute myeloid leukemia," is the first preclinical profiling of tuspetinib, a well-tolerated, once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML). The publication defines TUS activities on select oncogenic signaling targets, demonstrates enhanced activity and safety of TUS when combined with other agents, and illustrates synthetic lethality when combined with venetoclax (VEN). Pharmacokinetic and toxicology studies revealed that TUS is readily absorbed and achieves plasma concentrations sufficient to inhibit the target kinases, it has a plasma half-life that supports once daily dosing, and it demonstrates a favorable safety profile.
該出版物名爲 「用於治療急性髓系白血病的tuspetinib的臨床前開發」，是tuspetinib的首份臨床前分析。tuspetinib是一種耐受性良好、每日一次的口服激酶抑制劑，目前正在臨床開發中，用於治療急性髓系白血病（AML）。該出版物定義了TUS在特定致癌信號靶標上的活性，證明了TUS與其他藥物聯合使用時可增強的活性和安全性，並說明了與venetoclax（VEN）聯合使用時的合成殺傷力。藥代動力學和毒理學研究表明，TUS易於吸收，血漿濃度足以抑制靶激酶，其血漿半衰期支持每天給藥一次，並且表現出良好的安全性。
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib + venetoclax + azacitidine (TUS+VEN+AZA) triplet combination (NCT03850574). Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or the TUS+VEN combination have been completed.
Aptose現在正在招收新診斷的急性髓細胞白血病患者參加一項1/2期臨床研究，以接受塔斯佩替尼+ venetoclax + azacitidine（TUS+VEN+AZA）三聯體組合（NCT03850574）。對接受TUS單一藥物或TUS+VEN聯合治療的復發或難治性急性髓細胞白血病患者的臨床研究已經完成。
